Janney Montgomery Scott
ADAP

Janney Montgomery Scott’s Adaptimmune Therapeutics ADAP Stock Holding History

Janney Montgomery Scott’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-30,000
Closed -$29K – 2680
2024
Q3 		$29K Hold
30,000
– – ﹤0.01% 2630
2024
Q2 		$29K Hold
30,000
– – ﹤0.01% 2572
2024
Q1 		$47K Hold
30,000
– – ﹤0.01% 2681
2023
Q4 		$24K Hold
30,000
– – ﹤0.01% 2604
2023
Q3 		$23K Hold
30,000
– – ﹤0.01% 2532
2023
Q2 		$28K Hold
30,000
– – ﹤0.01% 2608
2023
Q1 		$33K Hold
30,000
– – ﹤0.01% 2424
2022
Q4 		$44K Hold
30,000
– – ﹤0.01% 2518
2022
Q3 		$32K Hold
30,000
– – ﹤0.01% 2465
2022
Q2 		$52K Hold
30,000
– – ﹤0.01% 2283
2022
Q1 		$62K Hold
30,000
– – ﹤0.01% 2205
2021
Q4 		$112K Hold
30,000
– – ﹤0.01% 2303
2021
Q3 		$155K Hold
30,000
– – ﹤0.01% 2197
2021
Q2 		$128K Hold
30,000
– – ﹤0.01% 2192
2021
Q1 		$159K Buy
+30,000
New +$172K ﹤0.01% 2086

Other funds holding ADAP

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Janney Montgomery Scott's ADAP Position: Q4 2024 in Review

Janney Montgomery Scott sold out of Adaptimmune Therapeutics (ADAP) in Q4 2024, closing a stake of 30,000 shares — an estimated $29K sold.

Janney Montgomery Scott first reported a position in ADAP in Q1 2021 and held it in 15 quarters. The position peaked at $159K in Q1 2021. 80 funds tracked by Wall St. Rank hold ADAP as of Q4 2024.

  • Janney Montgomery Scott reported no remaining Adaptimmune Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Janney Montgomery Scott sold 30,000 Adaptimmune Therapeutics shares in Q4 2024, an estimated $29K.
  • Janney Montgomery Scott first reported a position in Adaptimmune Therapeutics in Q1 2021 and held it in 15 quarters.
  • Janney Montgomery Scott's Adaptimmune Therapeutics position peaked at $159K in Q1 2021.
  • 80 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q4 2024.

Based on Janney Montgomery Scott's 13F filing for Q4 2024, filed 17 Jan 2025.